Ideaya Biosciences, Inc. progresses trials for uveal melanoma and solid tumors, with key upcoming data milestones. Click for ...

Based on promising preclinical data, researchers hope to begin clinically testing PLK1-targeted treatments in young people with fibrolamellar carcinoma.

President Donald Trump received heartbreaking news this week after making a promise to 17-year-old teenage germ cell cancer ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes ...

A rogue protein just yanked the plug on cancer’s energy grid. And researchers at the Duke University School of Medicine just ...

Research indicates that apples may possess anti-cancer properties due to compounds like triterpenoids, flavonoids, and ...

Learn the early warning signs of esophageal cancer that are often missed. Discover risk factors, treatment options and how to ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell ...

Sidney Raz shared his this reaction to backlash he received for announcing that he'd been diagnosed with stomach cancer back in April.

UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...